Alembic Pharmaceutical said that USFDA had conducted inspection at its oncology (injectable and oral solid) formulation facility (F-2) at Panelav,Gujarat.
The USFDA had conducted inspection from 28 February to 8 March 2024. At the end of the inspection USFDA issued a Form 483 with four procedural observations.The company said that it will provide comprehensive response to USFDA for the observations within the stipulated period.
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The drug maker recorded 48.01% jump in consolidated net profit to Rs 180.45 crore in Q3 FY23 as compared with Rs 121.92 crore in Q3 FY22. Revenue from operations slipped 8.05% year on year (YoY) to Rs 1,630.57 crore in the quarter ended 31 December 2023.
The scrip fell 0.04% to end at Rs 998.90 on Thursday, 7 March 2024.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app